Treatment patterns, complications, and disease relapse in a real-world population of patients with moderate-to-severe ulcerative colitis initiating immunomodulator therapy

Inflammatory Bowel Diseases

Volumn 20, Issue 8, 2014, Pages 1361-1367

  Loftus, Edward V ^a   Davis, Keith L ^b   Wang, Chi Chuan ^b   Dastani, Homa ^c   Luo, Allison ^c  

^a MAYO CLINIC   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Complications; Immunomodulators; Relapse; Treatment patterns; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; IMMUNOLOGIC FACTOR;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; CORTICOSTEROID THERAPY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG FEVER; DRUG UTILIZATION; FEMALE; HEMATOLOGIC DISEASE; HEPATITIS; HUMAN; HYPERTENSION; ICD-9-CM; IMMUNOMODULATION; INFECTION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MYELOPROLIFERATIVE DISORDER; NAUSEA AND VOMITING; PANCREATITIS; PARESTHESIA; PNEUMONIA; POPULATION; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; SEIZURE; TREMOR; ULCERATIVE COLITIS; UNITED STATES; CHEMICALLY INDUCED; COLITIS, ULCERATIVE; FOLLOW UP; GASTROINTESTINAL DISEASE; INFLAMMATION; MIDDLE AGED; PROGNOSIS; RECURRENT DISEASE; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COLITIS, ULCERATIVE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84905496700     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000089     Document Type: Article

References (19)

1. Kornbluth AA, Salomon P, Sacks HS, et al. Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis. J Clin Gastroenterol. 1993;16:215-218.
2. Meyers S, Janowitz HD. The "natural history" of ulcerative colitis: an analysis of the placebo response. J Clin Gastroenterol. 1989;11:33-37.
3. Herrinton LJ, Liu L, Lafata JE, et al. Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings. Inflamm Bowel Dis. 2007;13:451-461.
4. Herrinton LJ, Liu L, Lewis JD, et al. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002. Am J Gastroenterol. 2008;103:1998-2006.
5. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424-1429.
6. Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut. 2000;46:336-343.
7. Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis. 2007;13:254-261.
8. Ingle SB, Loftus EV, Tremaine WJ, et al. Increasing incidence and prevalence of inflammatory bowel disease in Olmsted County, Minnesota, during 2001-2004. Gastroenterology. 2007;132(4 suppl 2):A19-A20.
9. Sonnenberg A, Chang J. Time trends of physician visits for Crohn's disease and ulcerative colitis in the United States, 1960-2006. Inflamm Bowel Dis. 2008;14:249-252.
10. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907-1913.
11. Nguyen GC, Tuskey A, Dassopoulos T, et al. Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Dis. 2007;13:1529-1535.
12. Kornbluth AA, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters committee. Am J Gastroenterol. 2010;105:501-523.
13. Loftus EV Jr, Delgado DJ, Friedman HS, et al. Colectomy and the incidence of postsurgical complications among ulcerative colitis patients with private health insurance in the United States. Am J Gastroenterol. 2008;103:1737-1745.
14. Bowen GE, Irons GV Jr, Rhodes JB, et al. Early experiences with azathioprine in ulcerative colitis: a note of caution. JAMA. 1966;195:460-464.
15. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47-53.
16. Timmer A, McDonald JWD, Tsoulis DJ, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012:CD000478.
17. Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology. 1996;110:1416-1421.
18. Herfarth HH, Osterman MT, Isaacs KL, et al. Efficacy of methotrexate in ulcerative colitis: failure or promise. Inflamm Bowel Dis. 2010;16:1421-1430.
19. Rubin D, Goeppinger S, Kim S, et al. The CCFA National Survey of health care access in inflammatory bowel disease (IBD). Am J Gastroenterol. 2013;108(suppl 1):S532.